squalamine
Squalamine was discovered in a search for anti-microbial compounds in the tissues of primitive vertebrates. The team speculated that animals with primitive immune systems, such as sharks and lampreys, might utilize antimicrobial compounds as a significant component of their immune repertoire. The dogfish shark was the first shark species studied since it was accessible for research purposes at the Mount Desert Marine Biological Laboratory. In addition, large numbers of dogfish are harvested annually for consumption and could provide sufficient tissue for extraction during the early stages of compound isolation and characterization. The chemical synthesis was developed by William A. Kinney and colleagues,. — Wikipedia
Clinical trial activity
9 trials · 9 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2001 (NCT00021385)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@@H](NCCCNCCCCN)CC[C@]4(C)[C@H]3CC[C@]12C)OS(=O)(=O)O- Mol. weight
- 627.98 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSqualamine ↗
- ChEMBLCHEMBL444929 ↗
Also known as
- 3beta-n-1-(n-(3-(4-aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate
- squalamine
- squalamine
- squalamine
- squalamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02727881 | Phase 3 | Apr 12, 2016 | OHR Pharmaceutical |
| NCT02511613 | Phase 2 | Jul 1, 2015 | OHR Pharmaceutical |
| NCT02349516 | Phase 2 | Feb 1, 2015 | NJ Retina, OHR Pharmaceutical, Starr Muscle |
| NCT02614937 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Cumberland Valley Retina Consultants, PC, OHR Pharmaceutical |
| NCT01769183 | Phase 2 | Feb 1, 2013 | Elman Retina Group |
| NCT01678963 | Phase 2 | Nov 1, 2012 | OHR Pharmaceutical |
| NCT00139282 | Phase 3 | Jun 1, 2005 | Genaera Corporation |
| NCT00244920 | Phase 2 | Jan 1, 2002 | National Cancer Institute (NCI), Oregon Health and Science University |
| NCT00021385 | Phase 2 | May 1, 2001 | National Cancer Institute (NCI), University of California, Los Angeles |
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OHR Pharmaceutical | For profit | 5 | 4 | 2 | 2012 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2001 |
| Cumberland Valley Retina Consultants, PC | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Elman Retina Group | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Genaera Corporation | For profit | 1 | 1 | 1 | 2005 |
| NJ Retina | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Oregon Health and Science University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Starr Muscle | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of California, Los Angeles | Academic/Hospital | 1 | 1 | 1 | 2001 |